<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925817</url>
  </required_header>
  <id_info>
    <org_study_id>21-002713</org_study_id>
    <secondary_id>NCI-2021-04853</secondary_id>
    <secondary_id>21-002713</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04925817</nct_id>
  </id_info>
  <brief_title>3D Ultrasound Microvessel Imaging for Breast Masses</brief_title>
  <official_title>3D Ultrasound Microvessel Imaging for Breast Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well 3D ultrasound microvessel imaging works for the&#xD;
      diagnosis of breast mass. The 3D ultrasound microvessel imaging technology demonstrates&#xD;
      significantly increased vessel detection sensitivity over conventional doppler methods&#xD;
      without the need of using contrast agents. This study may improve cancer diagnosis and reduce&#xD;
      unnecessary biopsy on benign tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Optimization of imaging protocol for this new ultrasound technology. II. Investigate the&#xD;
      diagnostic performance of the new ultrasound technology using clinically indicated biopsy as&#xD;
      the reference standard.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo 3 dimensional (D) ultrasound microvessel imaging over 45 minutes. Patients'&#xD;
      medical records are reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound diagnostic accuracy using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be compared between conventional ultrasound (US) and conventional US + 3 dimensional (D) ultrasound microvessel imaging (UMI) using McNemar's test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters sensitivity using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include diagnostic performance parameters (sensitivity) calculated based on the BI-RADS score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters specificity using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Diagnostic sensitivity comparison between conventional US versus US + 3D-UMIl using the McNemar's test. Scale = Max 100%, Min 0% - The higher, the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters positive predictive value using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include diagnostic performance parameters (positive predictive value) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters negative predictive value using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include diagnostic performance parameters (negative predictive value) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better. .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters accuracy using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include diagnostic performance parameters (accuracy) calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters calculated by McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include Data System (BI-RADS) score calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultrasound parameters vs. Breast Image Reporting using McNemar's test</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will include Breast Imaging Reporting calculated based on the BI-RADS score. Scale = Max 100%, Min 0% - The higher, the better.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (ultrasound microvessel imaging)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3 D ultrasound microvessel imaging over 45 minutes. Patients' medical records are reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical record reviewed</description>
    <arm_group_label>Diagnostic (ultrasound microvessel imaging)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound Microvessel Imaging</intervention_name>
    <description>Undergo 3D ultrasound microvessel imaging</description>
    <arm_group_label>Diagnostic (ultrasound microvessel imaging)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with solid breast lesion who are scheduled for a clinically indicated&#xD;
             ultrasound-guided biopsy.&#xD;
&#xD;
          -  Lesion size of 1 cm or larger.&#xD;
&#xD;
          -  Age 18 or greater.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with previous breast surgery or breast implant.&#xD;
&#xD;
          -  Lacking the capacity to consent.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Women who are receiving cancer therapy such as chemotherapy or radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigao D Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shigao D. Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

